2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombosis
1
Thrombophilia
1
Thromboembolism
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Pulmonary Embolism
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Multiple Myeloma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Digestive System Diseases
1
Interventions
apixaban
22
Rivaroxaban
16
Dalteparin
16
Enoxaparin
11
Heparin, Low-Molecular-Weight
10
Tinzaparin
8
Aspirin
8
Fondaparinux
4
Dabigatran
4
edoxaban
3
Warfarin
3
Nadroparin
3
bemiparin
2
abelacimab
2
Rosuvastatin Calcium
2
Observation
2
MAA868
2
sotorasib
1
ribociclib
1
reviparin
1
palbociclib
1
isoquercitrin
1
enoxaparin sodium
1
certoparin
1
calcium heparin
1
betrixaban
1
argatroban
1
acarboxyprothrombin
1
abemaciclib
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Venous Thromboembolism
×
enoxaparin sodium
×
Clear all
NCT07270263
2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA
Recruiting
100 enrolled